Healthy ageing: ageing safely
Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
* Correspondence: B. M. Buckley M.D. D.Phil, PROSPER Centre, Department of Pharmacology and Therapeutics, University College Cork, 2200 Airport Business Park, Cork, Ireland.
b.buckley{at}ucc.ie
Abstract
The population of the developed world is steadily ageing. In the European Union, approximately 22% of persons are over 60 years of age and this is projected to increase to more than 27% by the year 2020. This has major implications for health care resources and the productive workforce. Ageing is accompanied by a decline in the physiological reserve of all organ systems, compromising homeostasis and resistance to disease. Thus, when disease develops in the elderly it has an increased impact on organ systems not directly involved. This places older people at risk for multiple simultaneous pathologies. Treatment often requires polypharmacy, which often is accompanied by drug interactions and adverse reactions. The pattern of sequential and comorbid disease often means that the later years of life are associated with an accumulating toll of disability, which in turn consumes a high proportion of health-care resources. The major goal of health care in the elderly should be to compress morbidity into the end of the normal lifespan. To achieve this, it will be necessary to redefine our approaches to treatment in the elderly and to develop an evidence base to inform this process.
Key Words: Ageing • dementia • drug interactions • 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) • polypharmacy
References
- United Nations. The Sex and Age Distribution of the World Populations, Volume II: Sex and Age, New York United Nations publication Sales No. E.99.XIII.8.
- United Nations. World Population Prospects, Volume II: Sex and Age. New York: United Nations publication; 1998.
- Larkin M. Robert Butler: championing a healthy view of ageing. Lancet. 2001;357:48–49[Medline]
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205
[Abstract/Free Full Text] - Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol. 1999;84:1192–1197[CrossRef][Web of Science][Medline]
- Sacks F, Pfeiffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
[Abstract/Free Full Text] - The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
[Abstract/Free Full Text] - Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in patients with hypercholesterolaemia. N Engl J Med. 1995;333:1301–1307
[Abstract/Free Full Text] - Gussekloo J, Heijmans BT, Slagboom PE, Lagaay AM, Knook DL, Westendorp RG. Thermolabile methylenetetrahydrofolate reductase gene and the risk of cognitive impairment in those over 85. J Neurol Neurosurg Psychiatry. 1999;67:535–538
[Abstract/Free Full Text] - Hitt R, Young-Xu Y, Silver M, Perls T. Centenarians: the older you get, the healthier you have been. [letter]Lancet. 1999;354:652[CrossRef][Web of Science][Medline]
- U.S. National Institutes of Health. Research for a New Age. http://www.nih.gov/nia/health/pubs/research/page4.htmstart
- Perry HM Jr., Davies BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465–471
[Abstract/Free Full Text] - Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. 2000;102:1139–1144
[Abstract/Free Full Text] - Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389[CrossRef][Web of Science][Medline]
- White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:317–326
[Abstract/Free Full Text] - Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women 62 years of age. Am J Cardiol. 1994;74:64–65[CrossRef][Web of Science][Medline]
- The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-arter bypass grafts. N Engl J Med. 1997;336:153–162
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||